Literature DB >> 19188379

Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug.

María P Sánchez-Cañete1, Luís Carvalho, F Javier Pérez-Victoria, Francisco Gamarro, Santiago Castanys.   

Abstract

Miltefosine (hexadecylphosphocholine, MLF) is the first oral drug with recognized efficacy against both visceral and cutaneous leishmaniasis. However, some clinical studies have suggested that MLF shows significantly less efficiency against the cutaneous leishmaniasis caused by Leishmania braziliensis. In this work, we have determined the cellular and molecular basis for the natural MLF resistance observed in L. braziliensis. Four independent L. braziliensis clinical isolates showed a marked decrease in MLF sensitivity that was due to their inability to internalize the drug. MLF internalization in the highly sensitive L. donovani species requires at least two proteins in the plasma membrane, LdMT, a P-type ATPase involved in phospholipid translocation, and its beta subunit, LdRos3. Strikingly, L. braziliensis parasites showed highly reduced levels of this MLF translocation machinery at the plasma membrane, mainly because of the low expression levels of the beta subunit, LbRos3. Overexpression of LbRos3 induces increased MLF sensitivity not only in L. braziliensis promastigotes but also in intracellular amastigotes. These results further highlight the importance of the MLF translocation machinery in determining MLF potency and point toward the development of protocols to routinely monitor MLF susceptibility in geographic areas where L. braziliensis might be prevalent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19188379      PMCID: PMC2663093          DOI: 10.1128/AAC.01694-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Short-course of oral miltefosine for treatment of visceral leishmaniasis.

Authors:  S Sundar; A Makharia; D K More; G Agrawal; A Voss; C Fischer; P Bachmann; H W Murray
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

2.  In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species.

Authors:  María Gabriela Cabrera-Serra; Jacob Lorenzo-Morales; Marialina Romero; Basilio Valladares; José E Piñero
Journal:  Parasitol Res       Date:  2007-01-06       Impact factor: 2.289

3.  Treatment of Bolivian mucosal leishmaniasis with miltefosine.

Authors:  J Soto; J Toledo; L Valda; M Balderrama; I Rea; R Parra; J Ardiles; P Soto; A Gomez; F Molleda; C Fuentelsaz; G Anders; H Sindermann; J Engel; J Berman
Journal:  Clin Infect Dis       Date:  2006-12-27       Impact factor: 9.079

Review 4.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

Authors:  François Chappuis; Shyam Sundar; Asrat Hailu; Hashim Ghalib; Suman Rijal; Rosanna W Peeling; Jorge Alvar; Marleen Boelaert
Journal:  Nat Rev Microbiol       Date:  2007-11       Impact factor: 60.633

5.  Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

Authors:  Patricia Escobar; Sangeeta Matu; Cláudia Marques; Simon L Croft
Journal:  Acta Trop       Date:  2002-02       Impact factor: 3.112

6.  Rapid transport of phospholipids across the plasma membrane of Leishmania infantum.

Authors:  José Ma Araújo-Santos; Francisco Gamarro; Santiago Castanys; Andreas Herrmann; Thomas Pomorski
Journal:  Biochem Biophys Res Commun       Date:  2003-06-20       Impact factor: 3.575

7.  Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.

Authors:  F Javier Pérez-Victoria; Santiago Castanys; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

8.  Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.

Authors:  Sujit Kumar Bhattacharya; Prabhat Kumar Sinha; Shyam Sundar; Chandreshar Prasad Thakur; Tara Kant Jha; Krishna Pandey; Vidyanand Rabi Das; Naveen Kumar; Chandrasekhar Lal; Neena Verma; Vijay Pratap Singh; Alok Ranjan; Rakesh Bihari Verma; Gerlind Anders; Herbert Sindermann; Nirmal Kumar Ganguly
Journal:  J Infect Dis       Date:  2007-06-29       Impact factor: 5.226

9.  Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.

Authors:  Karin Seifert; F Javier Pérez-Victoria; Marianne Stettler; María P Sánchez-Cañete; Santiago Castanys; Francisco Gamarro; Simon L Croft
Journal:  Int J Antimicrob Agents       Date:  2007-07-12       Impact factor: 5.283

10.  Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.

Authors:  Jaime Soto; Jaime Rea; Margarita Balderrama; Julia Toledo; Paula Soto; Luis Valda; Jonathan D Berman
Journal:  Am J Trop Med Hyg       Date:  2008-02       Impact factor: 2.345

View more
  30 in total

1.  Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.

Authors:  Maya Berg; Raquel García-Hernández; Bart Cuypers; Manu Vanaerschot; José I Manzano; José A Poveda; José A Ferragut; Santiago Castanys; Jean-Claude Dujardin; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Human TMEM30a promotes uptake of antitumor and bioactive choline phospholipids into mammalian cells.

Authors:  Rui Chen; Erin Brady; Thomas M McIntyre
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

Review 3.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

4.  Antileishmanial, antitrypanosomal, and cytotoxic screening of ethnopharmacologically selected Peruvian plants.

Authors:  Azucena González-Coloma; Matías Reina; Claudia Sáenz; Rodney Lacret; Lastenia Ruiz-Mesia; Vicente J Arán; Jesús Sanz; Rafael A Martínez-Díaz
Journal:  Parasitol Res       Date:  2011-09-16       Impact factor: 2.289

5.  Valeriana wallichii root extracts and fractions with activity against Leishmania spp.

Authors:  Subhalakshmi Ghosh; Sukalyani Debnath; Sudipta Hazra; Andreas Hartung; Katja Thomale; Martina Schultheis; Petra Kapkova; Uta Schurigt; Heidrun Moll; Ulrike Holzgrabe; Banasri Hazra
Journal:  Parasitol Res       Date:  2010-11-18       Impact factor: 2.289

6.  A new ABC half-transporter in Leishmania major is involved in resistance to antimony.

Authors:  J I Manzano; R García-Hernández; S Castanys; F Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

7.  Genome Sequencing of Leishmania infantum Causing Cutaneous Leishmaniosis from a Turkish Isolate with Next-Generation Sequencing Technology.

Authors:  Dilek Guldemir; Selma Usluca; Ayse Serpil Nalbantoglu
Journal:  Acta Parasitol       Date:  2020-07-20       Impact factor: 1.440

8.  The LABCG2 Transporter from the Protozoan Parasite Leishmania Is Involved in Antimony Resistance.

Authors:  Ana Perea; José Ignacio Manzano; Santiago Castanys; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

9.  Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.

Authors:  Ricardo Obonaga; Olga Lucía Fernández; Liliana Valderrama; Luisa Consuelo Rubiano; Maria Del Mar Castro; Maria Claudia Barrera; Maria Adelaida Gomez; Nancy Gore Saravia
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

10.  Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment.

Authors:  Dennis Tappe; Andreas Müller; August Stich
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.